United Kingdom

People: Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

18 Jul 2019
Change (% chg)

$0.10 (+2.72%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Houck, David 

Dr. David R. Houck, Ph.D is Chief Development Officer of the Company. He previously served as our Vice President for Drug Development Operations and Quality from August 2015 to April 2018 and has also served in that role in Naurex Inc. from May 2013 to August 2015. Prior to Naurex, Dr. Houck was president of PharmaKey, LLC from April 2009 until May 2013, and he currently serves as the chairman of its board of directors. Dr. Houck also serves on the editorial board on the Journal of Antibiotics. Dr. Houck has held scientific and managerial roles in several pharmaceutical companies including Merck & Company, Inc., Sanofi S.A., and OSI Pharmaceuticals, Inc. Dr. Houck received a B.S. in biology from Alma College, an M.S. in biochemistry from Purdue University, and a Ph.D. in chemistry from Ohio State University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --